The Parkinson’s Disease Therapeutics Market consequently describes the trade that is involved with the creation, manufacture and selling of products that are intended to alleviate the symptoms of Parkinson’s disease, a disease that is neurological in nature and causes difficulty controlling the body’s movements. This market also includes other drugs such as dopamine agonists, MAO-B inhibitors, COMT inhibitors and other anti-Parkinson treatments aimed at managing symptom and helping the patient to lead a better life. It also includes things such as deep brain stimulation (DBS) devices and patient monitoring systems. This market has been fueled by the growing number of people affected by Parkinson’s disease, the continuing development of new treatment methods, and relentless research into disease-altering agents.